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Amyotrophic lateral sclerosis (ALS) is a progressive, fatal neurodegenerative disorder 
characterized in pathology by a significant loss of upper and lower motor neurons, leading to muscle 
wasting and loss of voluntary movement. There are about 6,000-8,000 new cases of ALS diagnosed 
per year in the U.S., with a fatal outcome within 2 to 4 years (on average) after diagnosis. There are 
only two FDA approved drugs for treating ALS. Both are very expensive and only have modest 
benefits for patients. The population is in dire need of more affordable and effective medicine for the 
treatment of ALS.  
Therefore, the goal of this research was to test the viability of alginate nanofibers cross-
linked to non-toxic levels of calcium, barium, and strontium for the release of methylene blue as a 
potential novel drug delivery system for the treatment of ALS. Alginate possesses antioxidant 
activity, immunoregulatory activity, anti-inflammatory activity, and neuroprotective activity. 
Methylene blue also possesses antioxidant activity and has been shown to inhibit aggregation of 
TDP43, a protein that is aggregated in up to 97% of all ALS patients. These properties, in 
combination, would have great advantages for mitigating the multi-faceted pathogenesis of 
amyotrophic lateral sclerosis.  
The nanofibers were synthesized using immersive rotary jet spinning followed by 
lyophilization. Various concentrations (50 mM, 100 mM, 200 mM, 300 mM, and 400 mM) of cross-
linking cation were used to cross-link with 1% w/v alginate solution. Release studies with methylene 
blue occurred over a three-hour time period. Data were collected on the loading efficiencies, release 
profiles, and degradation times of the nanofibers using UV-Vis spectroscopy. Strontium 300 mM 
loaded with 31.2 µL of methylene blue had the highest loading efficiency at 59.9%. This nanofiber 
also loaded the most moles per milligram of nanofiber at 2.9 nanomoles/mg. Barium alginate 
nanofibers had the highest structural integrity followed by strontium then calcium. The release 
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kinetics of the nanofibers were inconclusive due to high error associated with each time point 
potentially due to redox reactions between alginate and methylene blue.  
Introduction 
 Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder that is 
part of a wider group of disorders known as motor neuron diseases.1 Motor neuron diseases 
(MNDs) are characterized by the gradual deterioration, dysfunction, and death of motor 
neurons.2 Along with ALS, progressive bulbar palsy, primary lateral sclerosis, Kennedy’s 
disease, and a few others are classified as MNDs.2 MNDs are categorized on several dimensions. 
The first is overarching etiology: inherited or sporadic.2 For ALS, inherited or familial ALS 
accounts for approximately 5-10% of all cases, whereas, approximately 90% of cases are 
considered sporadic.3  
The second dimension MNDs are categorized by are the neurons that are primarily 
affected.2 Motor neuron diseases can effecting upper, lower, or both types of motor neurons.2 
Classical ALS affects both the upper motor neurons, the neurons in the cerebral cortex that 
activate interneurons and lower motor neurons, and lower motor neurons, the neurons that 
directly signal muscles to contract or relax.2 The third category relates to the muscle group that 
symptoms initiate in. For ALS, symptoms start primarily in the limbs or bulbar (affecting 
muscles of the head and neck).4 Approximately 66% of ALS patients have spinal/limb onset and 
34% have a bulbar onset. 4 Early symptoms of spinal/limb onset ALS include muscle weakness 
or stiffness, tripping more than normal, and fasciculations.1 Whereas, early symptoms of bulbar 
onset ALS include difficulty chewing or swallowing, slurred speech (dysarthria), and difficulty 
breathing (dyspnea).1 The disease progresses to eventually affect all muscles needed to move, 
eat, speak and breathe.5 As the disease progresses about 50% of patients with ALS experience 
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cognitive or behavioral changes on the spectrum of frontotemporal dementia with apathy and 
loss of sympathy among the most common of behavioral symptoms.6 Eventually, ALS patients 
die of respiratory failure typically 2-4 years after the onset of symptoms.7 There is no cure for 
ALS at this point. 
Prevalence and Incidence of ALS 
 The global crude prevalence of ALS is 4.42 per 100,000 people, meaning roughly 4 
people out of every 100,000 people are affected by ALS.8 The global incidence is 1.59 per 
100,000 people per year.8 This translates to 2 people out of every 100,000 people diagnosed each 
year globally. The incidence and prevalence of males are higher than those in females.7 Possible 
reasons for the differences in prevalence and incidence of ALS between women and men include 
different exposures to toxins and different biological responses to the toxins.9 It is also possible 
that there are underlying differences between male and female nervous systems in how they 
repair damage.9 However, this has not been definitively determined.9 The incidence also grows 
by age globally with a peak at 60-70 years old.8 
In the United States, the prevalence of ALS is different than in other regions of the 
world.10 The prevalence is about 5.0 cases per 100,000 in the United States with the prevalence 
in Caucasians (5.4) more than twice of that observed in African Americans (2.4).10 Both 
prevalence and incidence are lowest in South Asia, however, the age of onset is much earlier.8 
The longest survival times post-diagnosis are also observed in South Asia.8  Developed regions 
have higher prevalence and incidence compared to developing or undeveloped regions.8 The 
observed difference in incidence may be due to the fact that developed regions have a higher 
mean age than developing regions.8  
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Several other factors besides geographical region have been identified as associated with 
ALS incidence and prevalence. In a study conducted by the NIH, occupations associated with 
higher socioeconomic status experienced greater ALS disease mortality.11 These occupations 
included mathematics, architecture, engineering, law, and education.11 Clustering of ALS has 
also been reported among American football players, Italian soccer players, and United States 
military veterans.12–14 It is thought that the four-fold increase of prevalence in American football 
players is due to strenuous physical activity and increased head injury, however, it could also be 
due to misdiagnosis of chronic traumatic encephalopathy.12 In a case-controlled study comparing 
road cyclists, professional basketball players, and professional soccer players only the soccer 
players displayed higher mortality due to ALS suggesting that the risk is not related to physical 
activity per se.14 Exposure to chemicals such as toxic herbicides or fertilizers as well as increased 
frequency of head injuries are theorized to be the cause of increased prevalence in soccer 
players.15  
Many studies have investigated environmental risk factors for ALS including exposures 
to solvents, degreasers, alcohols, insecticides, fertilizers, heavy metals, and pesticides because of 
their potential to explain sporadic ALS which accounts for the majority of ALS cases.15–17 
Overall, agricultural chemicals and pesticides have been repeatedly linked but have been based 
on poor methodology and self-report.17 Smoking, however, has been associated with an 
increased risk of ALS.18 There is a 9% increase in risk for every 10 years of smoking and a 10% 
increase for each additional 10 cigarettes smoked per day.18 This increase in risk could be due to 
direct neurotoxic effect on motor neurons or by increasing oxidative stress.18 The increased 
prevalence observed in United States military personnel could be due to increased exposure to 
detrimental lifestyle factors (e.g. smoking) and the increased proportion of men (96%).16 Other 
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military-specific exposures have been actively explored such as emotional/psychological trauma, 
exposure to transmissible agents, and physical trauma, however, there is not strong evidence that 
any particular military exposure serves as a risk factor for the increased mortality from ALS that 
is observed.16  
ALS cases are projected to increase by 69% in the next 20 years.19 This disease will 
continue to impact human lives at an increasingly larger scale due to the aging of the world’s 
population, improving healthcare, and economic conditions.19 Additionally, ALS is of increasing 
interest to the general population because of its high social impact. This is reflected by ALS 
being the 3rd most googled neurological disease in the United States in 2015.20 ALS also has a 
high economic impact. The economic burden results from the combination of frequent hospital 
admissions, rehabilitation, health care transport, medications, medical tests and examinations, 
reduction of working time, skilled home care, and early retirements.21 The total annual cost per 
patient with ALS is $69,475 in the US, $59,018 in Spain, and $47,092 in Germany.19,21,22 The 
costs increase with disease progression and not only reduce the patients’ quality of life but also 
the quality life of the caretakers.21,22  
The Etiology of ALS 
The etiology of the disease is just as enigmatic as the patterns of incidence and 
prevalence seen globally. Considerable progress has been made in unraveling the genetic 
etiology of ALS by identifying underlying genes. These genes include SOD1, TARDBP, FUS, 
OPTN, VCP, UBQLN2, C9ORF72 and PFN1.23 In combination, these genes explain 75% of 
familial cases and 11% of sporadic cases.23 Identifying the genetic etiology of ALS provides 
fundamental insights into the cellular mechanisms underlying neuron degeneration with each 
new gene providing another clue to the complexities of ALS. Superoxide dismutase 1’s (SOD1) 
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relation to ALS was discovered in 1993.24 This discovery lead to the development of the SOD1 
transgenic mouse model and opened research to the potential implication of oxygen free radicals 
as a pathogenetic mechanism for motor neuron death in familial and sporadic ALS.24  
However, human SOD1 ALS is thought to be distinct from that of other types of ALS 
because it lacks TDP43 and/or FUS pathology, two features that are present in nearly every other 
case of ALS.23 Abnormal aggregation TDP43 is a pathological feature present in most ALS cases 
(up to 97%) in which the protein that typically localizes to the nucleus for functioning in 
transcription becomes misfolded and aggregates in the cytosol.25 The protein is ubiquitinated and 
hyperphosphorylated resulting in amyloid-like aggregation, increased hydrophobicity, and 
sequestration of essential cellular components.25 These aggregates can be self-perpetuating 
operating in a prion-like mechanism.4 Although, mutations to the gene encoding TDP43, 
TARDBP, accounts for about 4% of familial cases the neuropathological changes associated 
with TDP43 are found much more frequently on autopsy.25 The fused in sarcoma (FUS) 
mutation shares functional homology with TDP-43 and accounts for 4% of familial cases.26 Their 
shared pathology of misfolding and erroneous localization to the cytosol emphasize the 
importance of abnormal RNA metabolism in motor neuron degeneration.23  
Other mutations linked to ALS have overlap with cases of Paget’s disease such as 
optineurin mutations, valosin-containing protein, and sequestosome 1 mutations.23,27 Mutations 
in ubiquitin 2 in both familial and sporadic cases implicate proteasome degradation of 
ubiquitinated proteins as a possible contributor to the pathology.28 A large intronic 
hexanucleotide repeat expansion in C9ORF72 accounts for 40% of familial ALS cases and 7% of 
sporadic cases in people of European ancestry.23 RNA foci are observed in patients with 
C9ORF72 which again implicates disruption of RNA metabolism through sequestration of RNA-
   
 
   
9 
 
binding proteins and other RNA species.29 On top of the plethora of implicated inherited 
mutations spontaneously occurring mutations have also been implicated in ALS.23  
The similarities in genetic architectures between familial and sporadic ALS has led to the 
view that rigid dichotomizing of ALS into familial and sporadic disease is outdated and 
oversimplified.4 Since the two types share many mechanisms of neurodegeneration including 
mitochondrial dysfunction, axonal transport, toxic protein aggregation, impaired protein 
degradation, prion-like spreading, excitotoxicity, oxidative stress, hypermetabolism, 
inflammation, and RNA metabolism defects.30 This evidence indicates that ALS is a clinically 
and genetically heterogeneous neurodegenerative syndrome with multiple underlying 
pathophysiological mechanisms.4  
Current Therapeutics for ALS 
The complexity underlying ALS has led to a variety of attempted treatments, however, 
none have been able to reverse neural damage and cure the disease despite the fact that the 
syndrome was first described more than a century ago in 1869.31 This does not mean that 
considerable effort has not been put towards finding a treatment. More than 60 molecules and 30 
genes have been implicated in the pathogenesis of ALS.17,23 These studies have led the discovery 
of for major of pathogenesis: excitotoxicity, inflammation, oxidative stress, and destruction of 
neurons.31  
Excitotoxicity  
The first avenue of clinical investigation was based on the hypothesis that aberrant 
glutamatergic system overactivation leads to death in motor neurons.32 This lead to clinical trials 
and eventually the FDA approval of riluzole in 1995.31 Riluzole’s mechanism is highly complex 
and modulates the glutamate receptors indirectly by modifying the sodium channel current, 
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potentiation of calcium-dependent potassium current, and inhibition of neurotransmitter 
release.33 Riluzole is estimated to be used by 50-75% of people with ALS.34 However, riluzole 
only has modest benefits, prolonging life span by a mere 2 to 3 months.33 In the United States, 
treatment with Riluzole costs about $10,000 USD per year and the cost effectiveness and quality 
of life of patients treated with Riluzole have not been assessed.33  
Neuroinflammation 
Numerous studies have investigated the immune system’s role in the pathogenesis of 
ALS. One study found microglial activation at the site of motor neuron damage in ALS patients 
and found a positive relationship between the intensity of microglial activation and motor neuron 
degeneration.35 An increase in the number of mast cells, another cell of the immune system, is 
associated with denervation of neuromuscular junctions and a feature consistently found in the 
muscles of ALS subjects.25,36 Additionally, the presence of infiltrating monocytes and 
macrophages increases as ALS progresses in SOD1 mice.35 Because neuroinflammation is a 
prominent pathological finding in ALS patients, eight compounds with primarily anti-
inflammatory actions have been assessed in their treatment for ALS patients.31 However, only 
one molecule has shown promise in late-stage clinical trials.31 This molecule, named masitinib, is 
a highly selective tyrosine kinase inhibitor that has prolonged survival in SOD1 model mice 
through preventing CNS neuroinflammation.31 In SOD1 mice, masitinib prevented mast cell and 
neutrophil infiltration, axonal pathology, and secondary-demyelination.36 The addition of 
masitinib to riluzole treatment in a clinical trial slowed functional decline in ALS patients by 
27%.37 Masitinib is currently deemed an orphan drug by the FDA and, therefore, is not currently 
being used to treat ALS.31  
 
   
 




Excessive production of reactive oxygen species and resultant oxidative stress has been 
implicated in the pathogenesis of ALS and was first considered in the pathology due to the 
discovery of mutated superoxide dismutase 1 in one-fifth of ALS cases.24,31 The finding of 
increased protein carbonyl levels in the spinal cord and motor cortex of patients with sporadic 
ALS, and increased 3-nitrotyrosine levels in SOD1 familial patients also implicate oxidative 
stress.38 Additionally, oxidative stress causes TDP43 and FUS delocalization from the nucleus to 
the cytoplasm and increases both proteins tendency to aggregate.39,40 One FDA approved drug 
currently is used to address oxidative stress in ALS patients: Edaravone. Edaravone is an 
intravenous free radical scavenger that has been proven to eliminate lipid peroxides and hydroxyl 
radicals that damage neuronal cells.41,42 It also mitigates the dysfunction of the blood-brain 
barrier in rats.42 Edaravone decreases oxidative stress as measured by a decrease in 3NT, a 
marker of oxidative stress. It has clinical significance for patients and leads to better scores on 
the ALSFRS-R, a measure specifically designed for the evaluation of functioning in ALS 
patients.41,43 Edaravone was approved in the USA in May of 2017 and was the first FDA-
approved treatment for ALS since the approval of riluzole in 1995.44 However, it has not been 
shown to reverse neuronal damage.44 Additionally, Edaravone has a rigorous treatment regimen 
requiring a cycle of two weeks of daily intravenous infusions followed by a period of two weeks 
drug-free.31 Edaravone costs $145,500 USD per year cost before insurance and typically requires 
patients to have a port placement for intravenous administration, assistance with travel, and 
sufficient time to sit through the treatment.44 These obstacles limit many patients from treatment 
and call for more accessible and effective treatments. 
 
   
 




Another avenue that many clinical trials have explored is the use of neurotrophic growth 
factors. Neurotrophic growth factors are active in neuron development, neural plasticity, 
neurogenesis, neural disease, and neural injury.45 Since amyotrophic lateral sclerosis has such 
complex pathophysiology without a single causative mechanism, protection of the motoneuron 
with neurotrophic factors has emerged as a rational approach. The three factors that have been 
investigated in humans are brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor 
(CNTF) and insulin-like growth factors (IGF-1).31 BDNF protects neurons against in vivo 
excitotoxicity, a key mechanism in ALS.46 CNTF has direct neuroprotective effects on 
degenerating motoneurons in stress-induced conditions.45,46 Whereas, IGF-1 is able to rescue 
motoneurons and reduce excitotoxicity.45 However, these neurotrophic factors were all 
investigated from 1995-2008 and another neurotrophic factor clinical trial has not occurred 
since.31 Importantly, the neurotrophic factors have been studied using various modes of delivery 
such as subcutaneous delivery and intrathecal administration but not through the use of drug-
loaded nanofibers.45 It is likely that poor dosage, ineffective delivery, and poor translation from 
mouse models could all be possible contributors to the failures of clinical trials involving 
neurotrophic factors.45 Therefore, a new drug delivery system that maintains consistent levels of 
drug at appropriately high doses needs to be developed and examined to determine if the 
promising effects of neurotrophic growth factors, current FDA approved drugs, and novel drugs 
can be improved upon in meaningful ways for ALS patients. 
Alginate Nanoscaffolds 
To mitigate problems with drug delivery and to address multiple of the identified disease 
mechanisms of amyotrophic lateral sclerosis, the current study focuses on developing and 
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optimizing a cross-linked alginate nanoscaffold for the effective delivery of drugs to 
amyotrophic lateral sclerosis affected motor neurons. Alginate was chosen as the primary 
material for the construction of this novel nanofiber scaffold because of its biocompatibility, low 
toxicity, relatively low cost, and the ability to be altered through relatively simple 
modifications.47 Additionally, alginate has a range of bioactivities such as anti-tumor properties, 
counteraction of oxidation, regulation of immune responses, reduction of inflammation, and 
neuroprotection.47  
Producing the scaffold on a nanoscale was chosen because many biological scaffolds 
present in the natural extracellular matrix in human tissue are on the nanoscale, therefore, this 
scale provides the highest similarity to natural systems.47 The nanoscale was also chosen because 
it allows for a large surface area per volume ratio and a very short diffusion distance for loaded 
drugs.48 
Alginate is a naturally occurring anionic polymer that is obtained from brown seaweed.49  
It is typically extracted from brown algae (Phaeophyceae), but other sources are utilized such as 
alginate producing bacterium.49 Polymeric nanofibers of alginate are of particular interest in 
regenerative medicine because they can be tailored to mimic the extracellular matrix in terms of 
structure, chemical composition, and mechanical properties.50 Alginate nanofibers bear 
resemblance to glycosaminoglycan, an abundant proteoglycan found in the extracellular matrix 
of humans, and can be used to provide similar mechanical support and to regulate cellular 
activities.50 The composition of the alginate varies depending on the natural source with differing 
ratios of its two sterically different repeating units: (1→4)-a-L-guluronate (G unit) and (1→4)-b-
D-mannuronate (M unit).50 These subunits are linked by β‐1,4‐glycosidic bonds.47 Only the 
guluronate blocks are believed to participate in intermolecular cross-linking with divalent cations 
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in a manner termed the egg-box model shown in Figure 1.49 Therefore, the composition 
sequence, G-block length, and molecular weight are all highly influential factors affecting the 
physical properties of alginate scaffolds.49  
Manipulation of molecular weight changes the physical properties of alginate fibers with 
higher molecular weight leading to greater mechanical strength due to increased cross-linking.49 
However, higher molecular weight also leads to low bioavailability.49 To circumvent this pitfall, 
degradation of alginate into oligosaccharides is utilized to increase the absorption of drugs and 
encourage biocompatibility.47 Additionally, alginate is often partially oxidized with sodium 
periodate to increase bioavailability, with the degree of oxidation strongly influencing the 
degradation of the fibers.49 A partially oxidized oligomer of alginate is shown in Figure 2.  
Cross-linking alginate can also increase biodegradability by the release of divalent ions 
and subsequent incorporation of monovalent cations present in the biological systems such as 
sodium.49 Ionic cross-linking is the most common method used for alginate cross-linking.49 The 
amount of cross-linking with alginate depends on the charge density of the ion and the number of 
guluronate blocks.49 Therefore, in this study oxidized oligosaccharides of alginate cross-linked to 
strontium, barium, and calcium were evaluated for their differences in drug release profiles and 
their ability to biodegrade.  
   
 




Figure 1: Schematic representation of the monomeric units of alginate (guluronate and 
mannuronate) and their interaction in an egg-box manner with the divalent calcium ion.49 
 
Figure 2: Schematic representation of chemical structures of alginate-derived oligosaccharide 
prepared by oxidative degradation.51  
The biological effects of alginate alone make it an attractive biomaterial for the treatment 
of amyotrophic lateral sclerosis. It possesses antioxidant activity, immunoregulatory activity, 
anti-inflammatory activity, and neuroprotective activity.47 All of which would be great utilities 
for mitigating the multi-faceted pathogenesis of amyotrophic lateral sclerosis which involves 
reactive oxygen species, neuroinflammation, dysregulation of cells of the immune system, and 
neurodegeneration.31,36 Several studies have documented alginate’s ability to inhibit oxidative 
stress-induced neurotoxicity in in vitro Alzheimer’s rat models as well as its ability to inhibit the 
formation of amyloid b.52 Alginate has also been implicated in immunoregulation through 
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induction of cytokine activity.53 Additionally, multiple studies have demonstrated alginate’s 
ability to activate macrophages and the host immune system.53,54 With its ability to influence the 
host’s immune system, alginate has subsequently been shown to suppress neuroinflammation by 
suppressing the activation of microglia and attenuating the production of inflammatory 
mediators.51 Alginate’s neuroprotective activity stems from its ability to inhibit oxidative stress 
and regulate the immune system, however, alginate is also an antiglycation agent.47 Advanced 
glycation end-products (AGEs) participate in the pathogenesis of neurodegenerative disorders 
and are associated with abnormal brain protein cross-linking, oxidative stress, and neuronal 
loss.47 These biological properties make it ideal to couple with a dynamic drug delivery system, 
in fact, alginate nanofibers have been investigated for their ability to deliver a variety of drugs. 
Alginate Nanoscaffold Release Kinetics 
The versatility of alginate oligosaccharide derivates can be exploited to regulate the 
kinetics of drug release.49 Alginate nanofibers are nanoporous.49 The nanopores allow for rapid 
diffusion of small molecules that can be altered as a function of amount of oxidization and cross-
linking. The goal of elucidating the release kinetics of varying alginate nanofibers to determine if 
they can maintain the drug level in the target tissue within the therapeutic window, above the 
minimum effective concentration and below the minimum toxic concentration, without the need 
for multiple doses.48 Often single large doses exceed the minimum toxic concentration but 
rapidly fall below the minimum effective concentration, therefore, a sustained release within the 
range is desirable.48 Providing the drug in one dose avoids fluctuations of drug concentration, 
reduces risk to the patient for repeated invasive delivery mechanisms, and avoids non-
compliance issues from the patient. Because sustained release at a low dosing frequency is 
desired zero-order drug release profiles (continuous release) are often pursued.48  
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As a biodegradable polymer alginate’s drug release occurs via three mechanisms: 
diffusion-controlled release, solvent-controlled release, and degradation-controlled release. 
Cross-linked alginate nanofibers incorporate drugs into its polymer matrix and the drug release is 
partially driven by the concentration differential across the membrane.50 Additionally, solvent 
transport into the drug carrier can displace the cross-linked cations used in alginate and initiate 
drug release.50 Water can also diffuse into the system resulting in the swelling of polymer 
followed by drug release.55 The release rate is determined by the relaxation rate of the polymers, 
the relaxation rate, in turn, relies on the amount of cross-linking.48  
Finally, degradation of the nanofiber also plays a role in the release kinetics. Although 
alginate is inherently non-degradable in mammals due to lack of the enzyme alginase, surface 
erosion and destruction of cross-linking structure degrade the polymer in biofluids.49 In 
nanofibers, the polymer degradation occurs faster because of the short distance water must travel 
to reach the interior of the fiber.48 Degradable polymeric systems are preferable because they can 
be readily removed from the body without causing harm. In fact, alginate oligosaccharides have 
the ability to be cleared by the kidney.56 The combination of these release types can then be 
evaluated concomitantly to determine if the release mechanism is Fickian or non-Fickian 
diffusion using the semi-empirical Peppas model illustrated in equation 1, where Mt is the 
cumulative amount of drug released at time t, M∞ is the cumulative amount of drug released at 
time ∞, k is a constant, and n is the order of the release. All of these values can be determined 
experimentally.48 Again, with zero-order release kinetics as the most favorable release profile for 
drug delivery. 
!!!" = 𝑘𝑡"     (1) 
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Alginate’s Current Applications 
Alginate has an extensive track record for biologically meaningful drug release in a 
variety of applications due to its adaptability and demonstrated benefits. Various alginate 
technologies have been applied for the regeneration of various tissues and been successful in the 
regeneration of blood vessels, bone, cartilage, muscles, nerves, pancreas, and liver.49,57,58 
Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) have a 
sustained and localized release from alginate fibers in applications related to increasing 
neovascularization in ischemic tissue.49 Alginate cross-linked with calcium has been used to 
sustain release of dibutyryl cyclic adenosine monophosphate and stromal cell-derived factor 1 in 
for wound healing.57  
Alginate has also demonstrated effective delivery of bone morphogenetic proteins 
(BMPs) to enhance osteogenic differentiation of bone-marrow derived cells in vitro.59 Sustained 
release of hepatocyte growth factor and fibroblast growth factor from alginate gels have 
enhanced long-term survival and outward migration of primary myoblasts in damaged muscle 
tissue and have supported extensive repopulation of host muscle tissues at the wound sites.58 
With the promising effects of alginate nanofibers on other tissues of the body, research has 
extended into the ability of alginate fibers to assist in the repair of the central and peripheral 
nervous systems. Alginate fibers incorporated into acute cervical spinal cord lesions in rats 
directed axonal growth, whereas, alginate gels were able to serve as a scaffold to restore a 50-
mm gap in cat sciatic nerves while promoting outgrowth of regenerated axons.60,61 Alginate 
nanofibers have also been evaluated in the context of their ability to fill up surgical residual 
cavities and were found to provide structural support and promote neural tissue reconstruction.62 
 
   
 




With the many successes of alginate biomaterials in tissue regeneration, and specifically 
their ability to act as a scaffold for neuron and axonal regeneration, this study focuses on 
analyzing various configurations of alginate nanofibers cross-linked with different cations. The 
properties of the nanofibers that were focused on were the loading efficiencies with the drug 
methylene blue, the release profiles, and degradation times. Methylene blue, the first synthetic 
drug, is a tricyclic phenothiazine.63 Under physiological conditions, methylene blue is a cation 
which makes it favorable for interaction with the anionic alginate nanofibers. Additionally, an 
extensive amount of literature has been published on methylene blue’s usefulness in treating a 
plethora of diseases including depression, enzymopenic hereditary methemoglobinemia, 
Ifosfamid-induced neurotoxicity, vasoplegic adrenaline resistant shock, and Alzheimer’s 
disease.63  
Particularly, methylene blue was chosen because it has been evaluated for its ability to 
slow down neurodegenerative diseases. Methylene blue has been found to inhibit the aggregation 
of tau protein and of Aβ peptides in the low µmol/L range; both of which are common in 
Alzheimer’s disease.64,65  However, what is most interesting is methylene blue has aggregation 
inhibitory potential for the protein TDP43, a protein that is aggregated in up to 97% of all 
amyotrophic lateral sclerosis patients.25,66 It is unclear whether the therapeutic use of methylene 
blue for neurodegenerative diseases is due to its aggregation inhibitory effect or the antioxidant 
activity by interaction with the electron transport chain, however, its positive effects remain 
relatively consistent.63 Additionally, behavioral and memory studies with rats have shown 
improvement without side effects for low doses of methylene blue.67 These positive effects of 
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methylene blue are assumed to be due to improved oxygen utilization via stimulation of 
mitochondrial cytochrome c oxidase.67  
Methylene blue is very inexpensive, can permeate the blood-brain barrier irrespective of 
the route of administration, and has approximately 73% bioavailability.68,69 Along with these 
properties and its potential prevention of TDP43 protein build up methylene blue was chosen as 
the model drug in the pre-clinical testing phases for this study. Methylene blue shares structural 
and dimensional similarities with the current FDA approved drugs for the treatment of 
amyotrophic lateral sclerosis. Their structural comparison can be seen in Figure 3. Therefore, it 
is ideal to use the much cheaper drug as a model for the characterization and development phase 
of alginate nanofibers so that the optimal nanofibers can then be applied and evaluated in vivo 
and in vitro with FDA approved drugs and methylene blue at a later time.  
 
Figure 3: Chemical Structures of Edaravone, methylene blue, and Riluzole, respectively. 
 The goal of this study is to synthesize and characterize alginate cross-linked nanofibers in 
their release of methylene blue. For that reason, no specific hypotheses were made about the 
ability of each type of nanofiber to load and release methylene blue. However, it was 
hypothesized that higher concentrations of cross-linking solution would lead to the synthesis of 
more robust nanofibers with longer degradation times.  
 
   
 





 An immersive rotary jet spinning system similar to the apparatus depicted in Figure 4 was 
used to synthesize the alginate nanofibers.70 The immersive rotary jet spinning system was built 
with the following parts: a 250-watt DC motor with variable speeds from 1000 to 80,000 RPM, a 
motor control board, a microcontroller, and a potentiometer. Changing the resistance of the 
potentiometer changed the voltages supplied to the motor. The rotating reservoir was 
manufactured from polysulfone and included one 175 μm diameter orifice. The speed of the 
rotating reservoir ranged from 15,000 to 65,000 RPM, while the collector reservoir spun at 350 
RPM. The reservoir for the precipitating bath was a 500 mL beaker on a stir plate with variable 
power to drive a stir bar. The precipitating bath used was a miscible liquid to the solution solvent 
but did not have the ability to solubilize the polymer. In this case, it was the varying cation 
chloride solutions, BaCl2, SrCl2, and CaCl2. The gap distance between the precipitating bath and 
the extrusion orifice, termed the air gap distance, was controlled independently by changing the 
height of the reservoir relative to the precipitating solution vortex. Lyovapor™ L-200 
Classic was used to lyophilize the samples. All samples were placed in 30 mg aliquots in VWR 
Glass vials with phenolic caps for further analysis.  
   
 




Figure 4: the immersion rotary jet-spinning system spins a nanofiber through an orifice of a 
rotating reservoir (a). In the air gap (b), the polymer solution undergoes jet elongation and 
thinning while the polymer chains align. After the jet elongation the polymer solution enters the 
cross-linking bath to form nanofibers. The vortex pull and collect the fibers in the precipitating 
bath.70  
VWR Scientific Sheldon Lab 1350FM Forced Air Oven Mint/ 240C/4 CuFt /4 Mo was 
used to maintain the samples at a constant temperature. A VWR Hot Plate Mini Reciprocal 
Shaker placed inside of the oven (Speed: 20 - 240 osc/min, Stroke: 1 in, Maximum Capacity: 40 
lbs, Controls: Digital, Bodine DC motor which drives the platform through a filtered SCR 
controller, Electrical: 230Vat 50/60hz, Dimensions: 16.5 x 11 x 10 in) was used to load the fibers 
with methylene blue under constant agitation. After the drug loading period, supernatant samples 
were analyzed with the Hitachi Photodiode Array Bio-spectrophotometer U-0080D (WL mode: 
1WL, wavelength: 663 nm, path length: 10 nm, integration: 32, High (abs): 1, low (abs): 1, high 
(nm): 800, low (nm): 500). The Hitachi High-Technologies Corporation 2003 Program No. 
7A00618-02 was used to analyze data. 
A low-power scanning electron microscope Tescan Vega II was used for confirmation of 
nanostructures. Additionally, a low-power x-ray powder diffraction Rigaku miniflex was used 
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for the routine check of known lattice-structures. An optical microscope Olympus BX51 was 
used to check samples before scanning electron microscopy.  
Required chemicals include sodium alginate (CAS: 9005-38-3, Sigma-Aldrich, St. Louis, 
MO), methylene blue solution 1% aqueous (CAS: 61-73-4, Ward’s Science St Catharines, ON, 
Canada), strontium chloride, anhydrous 95% powder (Beantown Chemical, Hudson, NH), 
calcium chloride, anhydrous 97% beads/powder (Beantown Chemical, Hudson, NH), and barium 
chloride dihydrate 99+% (Alfa Aesar, Heysham, LA3 2XY, England). Additionally, PBS tablets 
100 mL (VWR Chemicals, Solon, Ohio) with the composition of 137 mM sodium chloride, 2.7 
mM potassium chloride, and 10 mM phosphate buffer were utilized. 
Alginate Nanofiber Synthesis  
 Sodium alginate (Sigma-Aldrich St. Louis, USA) solutions of 1% weight/volume were 
made in 400 mL of deionized water and were heated with constant agitation for 1 hour. The 
crosslinking agents, strontium, barium, and calcium were prepared from SrCl2, BaCl2, and CaCl2 
at the following concentrations: 50 mM, 100 mM, 200 mM, 300 mM, and 400 mM. The varying 
concentrations were used to evaluate the mechanical integrity of the nanofibers relative to the 
degree of crosslinking as well as to examine the differing release profiles as the crosslinking 
agent changed in identity and in concentration. These precursor solutions were then used to 
obtain alginate nanofibers in which alginate solution was extruded from a reservoir into the 
crosslinking bath under a vortex created by immersive rotary jet spin, a centrifugal dry jet wet 
spinning platform. The synthesized alginate nanofiber scaffolds were then lyophilized below 
their glass transition temperature. Lyophilization has three primary stages: freezing phase, 
sublimation phase, and adsorption phase. The fibers are brought to temperatures below the triple 
point, then the pressure is lowered, and heat is added to the material so water will sublimate, then 
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ionically bound water molecules are removed by raising the temperature above that used in the 
sublimation phase. Lyophilization reduces drying times by 30% and can dry the nanofibers to 1-
5% residual moisture. The morphological properties of the nanofibers were assessed via 
scanning electron microscopy (SEM). The goal was to synthesize novel bioscaffolds as effective 
and neuroprotective agents with the desired pore structures and surface chemistry. 
Methylene Blue Loading and Release Studies 
 Methylene blue (methylthioninium chloride) was loaded to the fibers at various loading 
concentrations to determine the optimum dose. Loading concentrations that were assessed were 
12.2 nM, 48.8 nM, 97.5 nM. The methylene blue solutions were made with 1x phosphate-
buffered saline (PBS) to simulate the ionic environment of extracellular fluid. Phosphate 
buffered saline is commonly used in biological research and is a solution containing disodium 
hydrogen phosphate and sodium chloride. This solution helps to maintain a constant pH with 
osmolarity and ion concentration matching those of the human body (isotonic). The phosphate-
buffered solution was made using PBS tablets to minimize variation that comes with measuring 
the compounds with analytical balances. Approximately 30 milligrams of cross-linked alginate 
nanofibers were placed in the chosen loading concentration for 18 hours. During this time the 
samples were protected from light, maintained at 37oC, and were under constant agitation. These 
conditions were chosen to model extracellular conditions of the human nervous system which is 
maintained at similar conditions. Following the sample loading period, the samples were 
removed from the initial loading solution and washed twice with phosphate-buffered solution to 
mitigate the release of methylene blue and wash off weakly bound methylene blue. The 
methylene blue infused alginate nanofiber scaffolds were then ready for release studies.  
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 The methylene blue infused alginate nanofiber scaffolds were transferred using clean 
tweezers to 3 mL of fresh phosphate-buffered solution. The solution was then placed in the 
forced air oven where they were maintained at 37oC, protected from light, and were under 
constant agitation. At the same time, the loading solution was then analyzed using ultraviolet 
spectroscopy at 665 nm. Methylene blue has a maximum absorbance at 665 nm. This was 
determined before the beginning of release studies so that the absorbance value could serve as a 
proxy for the concentration of methylene blue in various solutions.  
To analyze the release profile of the methylene blue infused alginate nanofiber scaffolds, 
1.5 mL aliquots of the phosphate buffered solution containing the methylene blue infused 
alginate nanofiber were extracted at pre-determined time intervals (30, 60, 90, 120, 150, 180 
mins) using a micropipette. Once the aliquot was extracted for ultraviolet spectroscopy analysis, 
the same volume of 1x phosphate-buffered solution, 1.5 mL, was replaced to maintain the 
sample at a constant volume. The sample was then placed back into the oven to maintain the 
temperature at 37oC, protect it from light, and continue the agitation. Each nanofiber was 
analyzed in triplicate. 
Data Analysis 
 Molarity information about each of the sample aliquots will be obtained via calibration 






   
 




 Fourteen different configurations of alginate nanofibers were evaluated for their loading 
efficiency, release profiles, and degradation profile and are listed in Table 1. Selected fibers were 
analyzed with varying concentrations of methylene blue loading solutions. These solutions either 
consisted of 7.8 µL, 31.2 µL, or 62.4 µL of methylene blue in 20 mL of phosphate-buffered 
solution resulting in 12.2 nM, 48.8 nM, 97.5 nM methylene blue solutions, respectively. All 
nanofibers were analyzed morphologically with scanning electron microscopy to confirm the 
nanoporous and amorphous structure. A resulting micrograph of 200 mM strontium alginate is 
shown in Figure 5. Further macroscopic differences in fibers can be observed in methylene blue 
solutions in Figures 17-20 in the appendix. 
 
Table 1: Summary of evaluated alginate nanofibers. The left column represents the cross-linking 
cation and the top row represents the cross-linking cation’s concentration. The overlapping 
columns represent the loading concentration of methylene blue used for the nanofiber. 
 Cross-linking concentration 
Cation 50 mM 200 mM 300 mM 400 mM 
Strontium 31.2 µL 7.8 µL, 31.2 µL, 62.4 µL 31.2 µL, 62.4 µL  
Barium 31.2 µL 7.8 µL, 62.4 µL 31.2 µL 31.2 µL 
Calcium  31.2 µL 31.2 µL, 62.4 µL  
 
   
 




Figure 5: scanning electron microscope (SEM) image of 200 mM strontium alginate nanofibers. 
 The total loading efficiency of each nanofiber at varying loading concentrations was 
assessed via UV-Vis spectroscopy and calibration curve extrapolation. The nanofibers listed in 
Table 1 with their respective loading concentrations were analyzed. The total loading efficiency 
of the varying alginate nanofibers is of interest to minimize the amount of wasted loading drug 
and to determine which fiber effectively loads the greatest proportion of loading drug. The total 
loading efficiency of strontium alginate nanofibers peaked at 59.8% for 300 mM strontium cross-
linked nanofibers at 31.2 µL loading concentration. All other strontium alginate nanofibers 
maintained a loading concentration efficiency between 17% and 26% and were not significantly 
different from one another. The loading efficiency of strontium alginate nanofibers is depicted 
graphically in Figure 6, as well as the loading efficiency of barium and calcium alginate 
nanofibers. The barium alginate nanofibers also had the largest loading efficiency when the 
cross-linking solution was 300 mM and the loading solution contained 31.2 µL. The loading 
efficiency for that fiber was 35.2%, significantly lower than its strontium counterpart. However, 
it did not differ significantly from the loading efficiency of the 200 mM barium alginate 
nanofiber and both of these fibers had improved loading efficiency from the 400 mM barium 
alginate nanofiber. Of the three calcium alginate nanofiber configurations, the two with 
maximum loading efficiency were not significantly different from one another (calcium 200 mM 
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@ 31.2µL, 24.9%; calcium 300 mM @ 31.2µL, 22.6%). However, they both had greater loading 
efficiency than the 300 mM calcium @ 62.4µL (9.37%). These results are depicted in Figure 6. 
Figure 6: Total loading efficiency of Strontium, Barium, and Calcium cross-linked alginate 
nanofibers expressed as the percentage of loading methylene blue moles loaded onto the fiber 
after a 12-hour incubation period 
 
 To further standardize the analysis of the triplicate samples of each of the 14 nanofiber 
configurations, the nanofibers were analyzed for their loading efficiency per milligram of 
nanofiber. For the most part, the trends persisted that were described for total loading efficiency 
but were further differentiated from one another. The major change when analyzing on the 
milligram level was the loading efficiency of barium 200 mM @ 7.8µL. When standardizing by 
milligram this fiber conformed to the trend of lower loading efficiency than its strontium 
counterpart. The data depicting the percentage of total moles of methylene blue loaded per mg of 










































Type of Fiber and Loading Concentration
Total Loading Efficiency
Strontium Barium Calcium
   
 




Figure 7: Loading efficiency of a mg of strontium, barium, and calcium cross-linked alginate 
nanofibers expressed as the percentage of total methylene blue moles loaded onto a milligram of 
fiber in a 12 hour incubation period 
 To analyze the effective dose that could be loaded onto each type of nanofiber the moles 
of methylene blue loaded onto each milligram of nanofiber were analyzed. This information is 
important to ensure proper dosing of the target drug when applied in vivo. The maximum number 
of moles loaded per milligram of nanofiber was observed for strontium 300 mM @ 31.2µL with 
the ability to load about 2.79 nanomoles per milligram of nanofiber. When strontium alginate 
nanofibers were significantly different from their counterparts, they consistently outperformed 
their barium and calcium counterparts for ability to load the most moles. Barium nanofibers 
loaded the most moles in two conditions: 200 mM @ 62.4µL and 300 mM @ 31.2 µL with the 
ability to load about 1.5 nanomoles per mg of fiber. The trends in the number of nanomoles 
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Figure 8: The loading moles capacity of strontium, barium, and calcium cross-linked alginate 
nanofibers expressed as the amount of methylene blue moles loaded on a milligram of nanofiber 
in a 12-hour incubation period 
 The release profiles of the strontium, barium, and calcium alginate nanofibers were 
analyzed to determine the percentage of loaded drug released at 30-minute time intervals. The 
release profile is informative for determining if the fiber releases drug concentrations above the 
minimal toxic dose or if it consistently releases below the minimal effective dose. The goal for 
release is a consistent zero-order release profile that maintains drug concentrations between the 
minimal toxic dose and above the minimal effective dose. Two fibers of strontium alginate 
nanofibers, 200 mM @ 7.8µL and Sr 200 mM @ 62.4µL, showed rapid release profiles followed 
by degradation. Whereas, three strontium alginate nanofibers, Sr 200 mM @ 7.8µL, Sr 300 mM 
@ 31.2µL, and Sr 300 mM @ 62.4µL, had non-significantly different release profiles. These 
fibers showed slow release with a flattening after the release of 20.2-28.6% of all loaded 
methylene blue. Sr 300 mM @ 31.2µL nanofibers had very different release profile than the 
others resulting in the cumulative release of 78% of all loaded methylene blue. These trends are 
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Figure 9: Methylene blue release profile for various strontium cross-linked alginate nanofibers, 
represented by the percentage of loading methylene blue moles released at various time points. 
Data stopping before the 180-minute mark represent the degradation of the nanofiber. 
 Barium alginate nanofibers were also examined for their release profile until degradation. 
Barium 200 mM @ 7.8, barium 300 mM @ 31.2µL, and barium 400 mM @ 31.2 µL were not 
significantly different in their release profiles. Whereas barium 200 mM @ 62.4 µL showed the 
most prolonged and steady release of all the barium nanofibers. The barium 50 mM @ 31.2µL 
released methylene blue quickly as well as quickly degraded. The barium alginate nanofibers 
release profiles are depicted in Figure 10. Whereas, the release profiles of the three calcium 
alginate nanofibers are depicted in Figure 11. The two 300 mM calcium alginate nanofibers 
show very different release profiles; however, the 200 mM calcium alginate nanofiber is not 
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Figure 10: Methylene blue release profile for various barium cross-linked alginate nanofibers, 
represented by the percentage of loading methylene blue moles released at various time points. 
Data stopping before the 180-minute mark represent the degradation of the nanofiber. 
 
Figure 11: Methylene blue release profile for various calcium cross-linked alginate nanofibers, 
represented by the percentage of loading methylene blue moles released at various time points. 






















Barium Alginate Nanofibers Culumative Release
Barium 50 mM @ 31.2
Barium 200 mM @ 7.8
Barium 200 mM @ 62.4
Barium 300 mM @ 31.2























Calcium Alginate Nanofibers Culumlative Realease
Calcium 200 mM @ 31.2
Calcium 300 mM @ 31.2
Calcium 300 mM @ 62.4
   
 
   
33 
 
 To further standardize the comparison between fibers of the same type, the percent of 
total methylene blue moles loaded onto the fiber released was analyzed per milligram of 
nanofiber. This standardization reduced the differences observed in the strontium alginate 
nanofibers, however, the Sr 300 mM @ 31.2 µL and Sr 200 mM @ 62.4 µL remained 
significantly different from the other four fibers. This trend can be observed in Figure 12. With 
Sr 300 mM @ 31.2µL resulting in the most prolonged release and released the highest 
percentage of loaded moles into the surrounding solution and the Sr 300 mM @ 31.2µL resulting 
in a shorter release with less of the total moles released at the end of the study. 
 
Figure 12: Methylene blue release profile of strontium cross-linked alginate nanofibers 
represented by the percent of total moles loaded onto the nanofibers release at various time 
points. Data stopping before the 180-minute mark represent nanofibers that degraded. 
 The standardization to milligrams also produced a reduction in the difference among the 
barium alginate nanofibers as depicted in Figure 13. However, barium 200 mM @ 62.4 µL and 
barium 50 mM @ 31.2 µL continued to have the highest percent release that was significantly 
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Figure 13: Methylene blue release profile of barium cross-linked alginate nanofibers represented 
by the percent of total moles loaded onto the nanofibers release at various time points. Data 
stopping before the 180-minute mark represent nanofibers that degraded. 
 The calcium alginate nanofiber 300 mM @ 62.4 µL remained significantly different from 
the other two calcium alginate nanofibers when evaluated at the milligram level. The calcium 
alginate nanofiber trends are depicted in Figure 14.  
 The average degradation times of the nanofibers were also analyzed. Their degradation is 
an essential factor in their utility; however, it is optimal that the fibers do not degrade before 100 
percent of the loaded drug is released. Only the strontium 200 mM @ 62.4 µL nanofiber released 
100% of its loaded concentration before degradation and it did so rapidly. No other fiber 
achieved this. The trend in degradation time is depicted in Figure 15. Barium alginate nanofibers 
consistently took longer to degrade than the strontium alginate nanofibers except in the case of 
50 mM cross-linking solution in which they both degraded rapidly. Strontium alginate, in turn, 


















Percent Release per mg of Barium Alginate 
Nanofibers 
Barium 50 mM @ 31.2
Barium 200 mM @ 7.8
Barium 200 mM @ 62.4
Barium 300 mM @ 31.2
Barium 400 mM @ 31.2
   
 




Figure 14: Methylene blue release profile of calcium cross-linked alginate nanofibers 
represented by the percent of total moles loaded onto the nanofibers release at various time 
points. Data stopping before the 180-minute mark represent nanofibers that degraded. 
 
Figure 15: This statistical histogram depicts the average degradation time of differently cross-
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 The goal of this study was to identify the alginate cation cross-linked nanofiber with the 
highest loading efficiency for methylene blue, the highest capacity for moles loaded, had 
prolonged and steady release kinetics, and did not biodegrade before release was complete. The 
highest loading efficiency for methylene blue was observed for strontium 300 mM/31.2 µL at 
59.9%. This means the strontium 300 mM/31.2 µL fiber absorbed the highest proportion of 
methylene blue present in the loading solution and subsequently wasted the least amount of 
methylene blue. This is ideal because the drugs of interest, Edaravone and Riluzole, are very 
expensive and it would be in both the industry’s and patient’s best interest to increase loading 
efficiency to minimize wasted drug product.34,44 However, 59.9% is not near what would be 
optimal at an industrial level. Prompting the need for different configurations of alginate fibers to 
be tested. All strontium alginate nanofiber configurations outperformed their barium and calcium 
alginate nanofiber counterparts in loading efficiency. This trend became clearer when 
standardizing the alginate nanofibers down to the milligram. This standardization was necessary 
because triplicate samples of the same fiber often did not have the same exact weight and 
certainly did not have the same exact weight as the other two cation counterparts. The highest 
loading efficiency exhibited by a barium cross-linked alginate nanofiber was 35.2% for the 300 
mM/31.2 µL configuration. Whereas, the highest loading efficiency exhibited by a calcium 
cross-linked alginate nanofiber was 24.9% by the 200 mM/31.2 µL configuration. Barium cross-
linked alginate nanofibers often outperformed the calcium-cross-linked counterparts in loading 
efficiency. The trend of loading efficiency of strontium cross-linked alginate nanofibers had no 
clear pattern. However, when doubling the volume of methylene blue from 31.2 µL to 62.4 µL 
for the 300 mM strontium alginate nanofibers the loading efficiency reduced by about half. This 
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finding suggests that the 300 mM strontium alginate nanofibers had reached their maximum 
molar capacity at 31.2 µL and would only continue to load that same amount at 62.4 µL. The 
same phenomenon was exhibited by the 300 mM calcium alginate nanofibers. Barium alginate 
nanofibers did not have enough trials with the same type of nanofiber to make this comparison. 
However, it is likely that it reached its maximum ability to absorb methylene blue at 31.2 µL 
since the other two fibers exhibit that phenomena. 
 The number of moles loaded onto a milligram of alginate nanofiber is important to know 
for the appropriate dosing of drugs. The highest number of moles of methylene blue loaded onto 
a milligram of nanofiber was observed for 300 mM/31.2 µL strontium alginate at 2.79 
nanomoles/mg or 83.7 nanomoles per 30 mg of fiber. The nanofiber could realistically be much 
bigger, however, it would still fall short of methylene blue’s typical daily oral dosage of 625,293 
nanomoles.63 Further, the loading capability, if generalizable, would also fall short of 
Edaravone’s daily dosage of about 344,431 nanomoles and Riluzole’s daily dosage of about 
426,987 nanomoles.33,41  
It is important to note that the different modes of delivery, intrathecal administration 
versus the typical intravenous and oral administration, could potentially change the optimal drug 
dose. Strontium alginate nanofibers consistently loaded more nanomoles per mg of methylene 
blue than the barium and calcium alginate nanofiber counterparts. 300 mM strontium alginate 
nanofibers consistently loaded more moles than the strontium 200 mM counterpart. This could 
be due to tighter cross-linking within the higher concentration cross-linked fibers resulting in 
tighter nanopores in which methylene blue can enter. However, the same is not true for barium 
alginate nanofibers, which experienced maximal loading capacity for the 200 mM fibers and the 
300 mM barium fibers and comparable molar loading in the 50 mM and 400 mM barium alginate 
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nanofibers. This could be due to enhanced cross-linking making the nanopores too small for 
methylene blue molecules to effectively enter for the 400 mM barium alginate nanofibers and too 
large for the 50 mM barium alginate nanofibers. Barium alginate nanofibers consistently loaded 
more nanomoles of methylene blue per milligram of fiber than their calcium counterparts. Both 
calcium alginate nanofibers, 200 mM and 300 mM loaded non-significantly different numbers of 
moles. 
Release Profiles 
 The cumulative release profiles of the strontium, barium, and calcium alginate nanofibers 
revealed no obvious pattern. Nanofiber degradation inhibited data collection and release studies 
were stopped after significant nanofiber degradation inhibited the ability to collect samples for 
spectroscopy. For each cross-linking ion, strontium 200 mM/31.2 µL, barium 200 mM/62.4 µL, 
calcium 300 mM/62.4 µL, exhibited steady release. Barium 200 mM/62.4 µL exhibited the most 
ideal release profile of these. However, since the same fibers were analyzed at various loading 
concentrations it would be expected that the same nanofiber would have a similar release profile. 
This was not what was observed. For example, strontium 300 mM nanofibers release profiles 
were very dissimilar. The nanofiber loaded at 31.2 µL exhibited less total percentage release than 
the same nanofiber loaded at 62.4 µL. Similar trends are seen for barium 200 mM except that the 
fiber-loaded with 62.4 µL exhibited less total percentage release then when the fiber was loaded 
at 31.2 µL. On the other hand, nanofibers of different cross-linking concentrations displayed 
similar release characteristics. For example, barium 200 mM/7.8 µL, barium 400 mM/31.2 µL, 
and barium 300 mM/31.2 µL produced non-significantly different release profiles. Calcium 300 
mM/31.2 µL and calcium 200 mM/31.2 µL yielded the same results. These seemingly random 
release patterns could be due to the inherently amorphous structure of the alginate nanofibers 
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which can be observed in Figure 5. Different aliquots of the fibers could have different levels of 
structure effecting their ability to load and release methylene blue. For this reason, in future 
studies, a higher number of replicate samples would be beneficial to reveal a pattern of release 
profiles within these nanofibers. 
Degradation Profiles 
 The ideal degradation profile of these alginate nanofibers would involve nanofibers that 
remain their integrity just long enough to create a prolonged and sustained release of the loaded 
drug. To discern which nanofiber displayed the most ideal degradation pattern the average 
degradation times of the nine nanofiber types were measured. The two calcium-alginate 
nanofibers (200 mM, 300 mM) both degraded within an average of 60 minutes. The strontium 
alginate nanofibers exhibited a degradation pattern related to the cross-linking concentration. As 
the cross-linking concentration increased the average time of degradation also increased. The 50 
mM strontium nanofibers degraded the fastest (60 minutes), followed by 200 mM (130 minutes), 
and 300 mM (165 minutes). This pattern is what was suspected for the nanofibers. As the amount 
of cross-linking increases, the structural integrity of the nanofibers should also increase leading 
to slower degradation times.49 The barium alginate nanofibers also exhibited a cross-linking 
concentration-dependent relationship with degradation time. The barium alginate nanofibers 300 
mM and 400 mM degraded the slowest after 180 minutes, followed by barium 200 mM (165 
minutes) and barium 50 mM (60 minutes). However, higher concentrations can result in too high 
inhomogeneity of the network resulting in decreases in the network strength.71 This limit was not 
observed in this study, but it is possible that at cross-linking concentrations higher than 400 mM 
the degradation times would start to decrease.  
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When comparing the degradation times among different cross-linking cations it was also 
thought that stronger ionic interactions between cations of higher charge density would result in 
stronger cross-linking to the negative carboxylic acid groups of alginate and longer degradation 
times. This was not the result. Calcium had the highest charge density of 52 C mm-3, followed by 
strontium at 33 C mm-3, and barium at 23 mm-3. Interestingly, despite calcium having the highest 
charge density, it degraded the quickest and despite barium having the lowest charge density it 
had the highest integrity. Instead, the degradation profile seems to be more closely related to the 
atomic radius. Calcium has an atomic radius of 231 pm, strontium has an atomic radius of 255 
pm, and barium has an atomic radius of 268 pm.71 As atomic radius increased the fibers’ 
degradation time also increased. Qualitatively, a more stable metal-ligand bond with barium 
exhibited a larger bond strength and a longer bond lifetime, whereas, strontium and calcium 
exhibited a less stable and more transient association. This is in line with alginate’s proven 
affinity toward different divalent ions which has been shown to decrease in the following order: 
Ba > Sr > Ca.71 
Limitations 
 There are some key limitations to this study. First, there are clear gaps in the data. Data 
for calcium 50 mM, calcium 400 mM, and strontium 400 mM nanofibers were not collected but 
would have been beneficial to the comparison of nanofibers above. Nanofibers for all cations 
cross-linked at 100 mM would have also added to a more complete characterization of these 
nanofibers. These missing fibers should have been analyzed at all three loading concentrations 
12.2 nM, 48.8 nM, 97.5 nM to determine optimal loading concentration. Data for synthesized 
nanofibers at all different loading concentrations would have been beneficial for a more 
complete analysis and include: calcium 200 mM/12.2 nM, calcium 200 mM/97.5 nM, calcium 
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300 mM/12.2 nM, strontium 300 mM/12.2 nM, strontium 50 mM/48.4 nM, strontium 50 
mM/97.5 nM, barium 50 mM/12.2 nM, barium 50 mM/97.5 nM,  barium 300 mM/48.8 nM, 
barium 300 mM/12.2 nM, barium 300 mM/97.5 nM, barium 400 mM/12.2 nM, and barium 400 
mM/97.5 nM.  
The cumulative release profiles of the different alginate nanofibers produced no 
explainable patterns. In the laboratory oftentimes, the alginate nanofibers would look as though 
they released all loaded methylene blue. This was observable by the color change of the 
nanofibers from a dark blue to white. However, the release study analysis would show that only 
20-30% of methylene blue was released. The phenomenon could be due to photobleaching of the 
dye. This interrupts data analysis significantly because the means of quantification of methylene 
blue is with UV-Vis spectrometry. 
 Third, these nanofibers were evaluated for their release profile of one non-FDA approved 
drug for the treatment of amyotrophic lateral sclerosis. Therefore, it does not mean that these 
nanofibers would exhibit similar loading efficiencies, molar capacities, release kinetics, or 
biodegradation patterns with Riluzole and Edaravone. Additionally, the nanofibers would also 
need to be examined for their release profiles of important macromolecules for neuroprotection 
such as brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF) and 
insulin-like growth factors (IGF-1). This method of neurotrophic factor delivery has not been 
tested thus far and the addition of a scaffolding structure of alginate could further improve the 
beneficial effects of NFs. These molecules would likely have a different optimal alginate 
nanofiber configuration than the optimal alginate nanofiber used for smaller molecules such as 
methylene blue.  
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 These nanofibers would eventually be evaluated in vivo and in vitro. Conditions in which 
in vitro drug release kinetics are tested and in which the nanofibers were tested in this study are 
performed in buffered saline. However, buffered saline (or phosphate-buffered solution) barely 
reflects the complexity of bodily fluids which contain proteins and lipids and can greatly 
challenge the stability of the nanocarriers. Consequently, it is often observed that drug release in 
serum complemented cell culture or in blood occurs much faster than predicted in buffered 
saline.72 This could mean that nanofibers showing favorable release kinetics with sustained drug 
release between the minimal effective dose and below the minimal toxic dose in release studies 
such as this one, could have suboptimal release profiles when transitioned to in vivo systems. In 
the future, conditions for developing these alginate nanofibers and studying the release kinetics 
should more closely model the complexity of bodily fluids, particularly cerebrospinal fluid.  
 There is also a potential for the cross-linked cations to disrupt the biological system they 
are inserted into as the alginate nanofibers degrade and ions release into the surrounding 
environment. This is of particular concern for the cation barium. The permissible eight-hour 
exposure to barium is 0.5 mg/m3 and the level that is immediately dangerous to life or health 50 
mg/m3.73 The mechanisms involved in barium positioning are likely related to the metabolic 
control of potassium levels leading to hypokalemia.73 Hypokalemia has adverse cardiovascular 
and muscular effects including tachycardia, changes in blood pressure, muscle weakness, and 
paralysis.73 Therefore, the amount of barium present needs to be closely monitored during these 
release studies to ensure that barium cross-linked nanofibers do not lead to barium toxicity. 
 Further limitations to this study are due to the methods. Release studies were unable to 
occur over periods of more than three hours due to incomplete but extensive degradation of the 
nanofibers. This issue could have been avoided by increasing the amount of phosphate-buffered 
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solution and the sample vial size during release studies from 3 mL to 20 mL. This increase in 
volume would make it easier to obtain samples of the appropriate size (1-1.5 mL), with fewer 
pipette draws, that were free of degradation particulates for analysis by ultraviolet-visible 
spectrometry. Due to this limitation in vial size, degradation particulates could have been in 
samples that were analyzed in this study and potentially interfered with the quality of the data.  
The methylene blue solution (Ward’s Science) purchased for this study was designed for 
educational and teaching laboratories and had no certificate of analysis available. Therefore, this 
solution was most likely better suited for qualitative rather than quantitative studies. In future 
studies, the methylene blue purchased should be one that has a certificate of analysis such as 
those supplied by Spectrum Chemical MFG Corp.  
Future Directions 
 Alginate is an adaptable biopolymer and its properties vary greatly based on source, 
cross-linking material, and preparation technique.49 This study only explored one avenue: cross-
linking three divalent cations in 1% alginate solutions. However, alginate has the ability to 
participate in covalent cross-linking and can be prepared at various concentrations to create 
different cross-linking densities and release profiles. These avenues should be explored for their 
applications to neural scaffolds and targeted drug release as it will be a continual challenge to 
match the physical properties of the alginate nanofiber to the particular application. One avenue 
that can be directly explored via an extension of this study is cross-linking alginate to mixtures 
calcium, strontium, and barium at different relative proportions to see if the release kinetics 
change favorably. Alginate solutions of different weight/volume content can also be investigated 
using the same cation cross-linking protocol as in this study. Further properties of alginate 
nanofibers can be explored through covalently cross-linking various reagents to the nanofiber, 
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such as poly(ethylene oxide). These different cross-linking polymers have the ability to 
significantly alter the release properties of the nanofibers. In fact, it is very difficult to reach the 
specified dosing targets for prolonged release of drugs using unipolymer nanofibers.74 Other 
polymers that have seen success with alginate are poly(ethylene oxide), poly(ethylene glycol) 
and chitosan.50 Poly(ethylene oxide) creates a less viscous alginate solution.50 Poly(ethylene 
glycol) affects the mechanical properties and swelling of alginate nanofibers.49 Whereas, 
chitosan cross-linked alginate results in a lower swelling ratio, increased cell adhesion, and 
increased cell proliferation compared to alginate nanofibers alone.74 All of these properties can 
be utilized to further optimize alginate nanofibers. 
 More characterization of the various nanofibers also needs to take place to fully 
understand all of the contributing properties to the release kinetics and the integrity of the 
nanofiber mats. These physical properties of the nanofiber can be accessed by measurement of 
the density, uniformity, surface roughness, and mechanical strength.74 Fiber properties such as 
morphology, arrangement, and surface features can also impact drug release kinetics.74 These 
properties need to be included in the analysis of synthesized nanofibers in the future to better 
understand their effect on drug release. Scanning electron microscopy (SEM) and transmission 
electron spectroscopy (TEM) should be used to measure fiber size, size distribution, fiber 
alignment, and to visualize crystalline drug dispersed in the fibers.74 X-ray photoelectron 
spectroscopy (XPS) can probe the surface chemistry of the nanofibers to quantify the amount of 
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Figure 16: comparison of 50 mM Strontium, 50 mM Barium, and 300 mM calcium alginate 
nanofibers macroscopic features after 12 hours of incubation in methylene blue. 
 
Figure 17: Comparison of 300 mM Barium alginate nanofibers loaded with methylene blue (top) 
versus not loaded (bottom). 
 
Figure 18: comparison of 50 mM Strontium, 50 mM barium, and 300 mM calcium cross-linked 
alginate nanofibers macroscopic morphological features after a 12-hour incubation period in 
methylene blue. 
   
 




Figure 19: Comparison of the macroscopic morphological properties of Calcium 200 mM cross-
linked alginate (left), barium 400 mM cross-linked alginate (middle), and strontium 200 mM 
cross-linked alginate nanofiber (right) in PBS solution at the start of a drug release study. 
